Larvol Delta - Solid-Tumor-Patient-Response-in-Second-Higher-Dose-Cohort

prexigebersen-A (BP1001-A) - Bio-Path

https://www.globenewswire.com/news-release/2025/02/13/3025827/0/en/Bio-Path-Holdings-Provides-Key-Clinical-Updates.html

Feb 13, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next